Single-dose pegfilgrastim for the mobilization of allogeneic CD34 + peripheral blood progenitor cells in healthy family and unrelated donors

Haematologica

Volumn 90, Issue 12, 2005, Pages 1665-1671

  Kroschinsky, Frank ^a   Hölig, Kristina ^a   Poppe Thiede, Kirsten ^a   Zimmer, Kristin ^a   Ordemann, Rainer ^a   Blechschmidt, Matthias ^a   Oelschlaegel, Uta ^a   Bornhauser, Martin ^a   Rall, Gabi ^c   Rutt, Claudia ^b   Ehninger, Gerhard ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DKMS German Bone Marrow Donor Center   (Germany)

^c DKMS ^*

Author keywords

Allogeneic donors; Pegfilgrastim; Stem cell mobilization

Indexed keywords

ALKALINE PHOSPHATASE; CD34 ANTIGEN; LACTATE DEHYDROGENASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BODY WEIGHT; BONE PAIN; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; FAMILY; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKAPHERESIS; LYMPHOCYTE COUNT; MALE; NORMAL HUMAN; PERIPHERAL BLOOD STEM CELL; RECIPIENT; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; SWEATING; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD34; DRUG EVALUATION; FEMALE; FILGRASTIM; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INTERLEUKIN-10; LEUKAPHERESIS; LEUKOCYTE COUNT; LIVING DONORS; MALE; MIDDLE AGED; MONOCYTES; PAIN; PAIN MEASUREMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SPLENOMEGALY; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 29144453285     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Arbona C, Prosper F, Benet I, Mena F, Solano C, Garcia-Conde J. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998;22:39-45.
2. Kroger N, Zeller W, Hassan HT, Kruger W, Gutensohn K, Loliger C, et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2×5 μg/kg) compared to a single dose (1×10 μg/kg). Bone Marrow Transplantation 1999;23:125-9.
3. Kröger N, Renges H, Krüger W, Gutensohn K, Löliger C, Carrero I, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000;111:761-5.
4. Lee V, Li CK, Shing MMK, Chik KW, Li K, Tsang KS, et al. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases. Bone Marrow Transplantation 2000;25:931-5.
5. Kroger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, Zander AR. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 2004;44:104-10.
6. Tanaka J, Miyake T, Shimizu T, Wakayama T, Tsumori M, Koshimura K, et al. Effect of continuous subcutaneous administration of a low dose of G-CSF on stem cell mobilization in healthy donors: a feasibility study. Int J Hematol 2002;75:489-92.
7. Curran MP, Goa KL. Pegfilgrastim. Drugs 2004;62:1207-15.
8. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
9. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31.
10. De Haan G, Ausema A, Wilkens M, Molineux G, Dontje B. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Haematol 2000;110:638-46.
11. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, et al. Randomized, dose-esacalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8.
12. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1727-34.
13. Kroschinsky F, Hölig K, Platzbecker U, Schleyer E, Ordemann R, Haack A, et al. Single-dose pegfilgrastim after chemotherapy is highly effective in enhancing the mobilization of CD34+ peripheral blood stem cells in patients with lymphoid malignancies and solid tumors. Blood 2004;104:[abstract 2922].
14. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005;90:225-31.
15. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplantation 2005;35:33-6.
16. Sutherland D, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996;5:213-26.
17. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999;39:555-60.
18. Fischer JC, Kiesel U, Platz A, Herda A, Frick M, Wernet P. A comparison of filgrastim and lenograstim in a phase III study: yields or G-CSF mobilized PBPC from unrelated donors. Blood 2002;100:[abstract3265].
19. Kröger N, Renges H, Sonnenberg S, Krüger W, Gutensohn K, Dielschneider T, et al. Stem cell mobilization with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002;29:727-730.
20. Beelen DW, Ottinger H, Kolbe K, Pönisch W, Sayer HG, Knauf W, et al. Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study. Ann Hematol 2002;81:701-9.
21. Ordemann R, Hölig K, Wagner K, Rautenberg U, Bornhäuser M, Kroschinsky F, et al. Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. Bone Marrow Transplant 1998;21 Suppl 3:25-8.
22. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-5.
23. Stroncek DF, Clay ME, Smith J, Ilstrup S, Oldham F, McCullough J. Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors. Transfusion 1996;36:596-600.
24. Picardi M, De Rosa G, Selleri C, Scarpato N, Soscia E, Martinelli V, et al. Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica 2003;88:794-800.
25. Engelhardt M, Bertz H, Wäsch R, Finke J. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus Targe volume apheresis for allogeneic transplantation. Ann Hematol 2001;80:201-8.
26. Morris ES, MacDonald KP, Rowe V, Johnston DH, Banovic T, Clouston AD, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004;103:3575-81.
27. Couban S, Barnett M. The source of cells for allografting. Biol Blood Marrow Transplant 2003;9:669-73.
28. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.
29. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000;18:537-46.